SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, two platforms to streamline and enhance personalized cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group.